InSyBio is an international biotechnology pioneer company in precision medicine and nutrition, which focuses on providing on the identification of biosignatures and diagnostic/prognostic tests for cancer, neurodegenerative diseases, cardiovascular diseases, chronic pain and diagnosis.

Its unique bioinformatics and machine learning biomarker discovery solutions provide the R&D departments of Pharma, Research Institutes (such as the Nestlé Institute of Health Sciences) and Food/Nutrition companies, with the means both analytically and computationally to meet their challenging research goals: robust biomarker discovery and accurate predictive models. Since 2013, InSyBio has worked with hundreds of academics, companies, hospitals and research centers allowing them to succeed in their biomarker discovery tasks with an average increase of 10% in predictive accuracy and decrease of at least 80% in overall time and cost.

Offering tools for biomarker discovery, biological data management, secured storage and computational bio-data analysis, our mission is to accelerate preclinical and clinical studies of pharmaceutical companies as well as to provide precise solutions for biomarker discovery in nutrition industry, biotechnology industry and academia. For this reason, we are striving for the continuous production of intelligent and innovative algorithms to assist our customers in inferring knowledge from experimental data. Being a young company, InSyBio aspires to contribute to the development of the globalized orientation of entrepreneurship through its association and cooperation with academic, research and business organizations worldwide. At InSyBio, we are passionate about supporting our customers to minimize their efforts, as they design and develop new drugs, nutritional products, therapeutic and diagnostic methods.